Table 12.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1994 to 2003

Recipients with Lung Transplants

  Year of Transplant
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 740 893 836 948 893 922 977 1,083 1,054 1,099
Tx with Antirejection Treatments 390 475 381 421 402 397 432 500 428 354
Antibodies Any in Category 17.7% 9.5% 10.8% 11.6% 15.9% 16.1% 18.8% 11.4% 13.3% 16.4%
ALG 1.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 10.5% 5.7% 7.3% 7.8% 10.9% 8.1% 7.4% 4.2% 3.0% 5.1%
OKT3 7.7% 4.2% 3.7% 4.3% 3.2% 3.0% 2.5% 1.4% 1.9% 0.8%
Thymoglobulin 0.0% 0.2% 0.0% 0.0% 0.7% 5.0% 5.8% 6.0% 4.9% 5.6%
Zenapax 0.0% 0.0% 0.0% 0.2% 2.2% 1.0% 3.0% 0.8% 5.1% 7.1%
Simulect 0.0% 0.0% 0.0% 0.0% 0.2% 0.8% 2.8% 0.6% 0.2% 0.6%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.5% 0.6%
Corticosteroids Any in Category 92.6% 93.7% 90.0% 94.1% 91.5% 92.9% 88.2% 92.4% 94.9% 96.3%
Steroids 92.6% 93.7% 90.0% 94.1% 91.5% 92.9% 88.2% 92.4% 94.9% 96.3%
Antimetabolites Any in Category 3.1% 1.1% 5.0% 1.9% 0.7% 1.5% 1.2% 1.2% 0.2% 1.4%
Cytoxan 0.8% 0.0% 0.8% 0.5% 0.2% 0.8% 0.5% 0.2% 0.2% 0.6%
Methotrexate 2.3% 1.1% 4.2% 1.4% 0.5% 1.5% 0.7% 1.0% 0.0% 0.8%


Source: OPTN/SRTR Data as of May 2, 2005.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.